- Home
- APLM vs MYNZ Comparison
APLM vs MYNZ Comparison
Compare APLM & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- MYNZ
- Stock Information
- Founded
- APLM 2016
- MYNZ 2021
- Country
- APLM United States
- MYNZ Germany
- Employees
- APLM N/A
- MYNZ N/A
- Industry
- APLM Blank Checks
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- APLM Finance
- MYNZ Health Care
- Exchange
- APLM Nasdaq
- MYNZ Nasdaq
- Market Cap
- APLM 6.1M
- MYNZ 5.1M
- IPO Year
- APLM N/A
- MYNZ 2021
- Fundamental
- Price
- APLM $5.80
- MYNZ $1.72
- Analyst Decision
- APLM
- MYNZ Buy
- Analyst Count
- APLM 0
- MYNZ 2
- Target Price
- APLM N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- APLM 47.7K
- MYNZ 165.8K
- Earning Date
- APLM 08-18-2025
- MYNZ 08-19-2025
- Dividend Yield
- APLM N/A
- MYNZ N/A
- EPS Growth
- APLM N/A
- MYNZ N/A
- EPS
- APLM N/A
- MYNZ N/A
- Revenue
- APLM $198,000.00
- MYNZ $893,991.00
- Revenue This Year
- APLM $415.15
- MYNZ $26.06
- Revenue Next Year
- APLM N/A
- MYNZ $4.97
- P/E Ratio
- APLM N/A
- MYNZ N/A
- Revenue Growth
- APLM N/A
- MYNZ N/A
- 52 Week Low
- APLM $4.47
- MYNZ $1.30
- 52 Week High
- APLM $35.98
- MYNZ $18.40
- Technical
- Relative Strength Index (RSI)
- APLM 47.28
- MYNZ 51.63
- Support Level
- APLM $5.41
- MYNZ $1.41
- Resistance Level
- APLM $6.38
- MYNZ $1.60
- Average True Range (ATR)
- APLM 0.44
- MYNZ 0.16
- MACD
- APLM -0.01
- MYNZ -0.01
- Stochastic Oscillator
- APLM 31.20
- MYNZ 54.55
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.